HNSPF (Hansoh Pharmaceutical Group Co) ROCE %: 17.26% (As of Dec. 2025)


HNSPF Hansoh Pharmaceutical Group Co Ltd HNSPF
90 GF Score
Price $3.83
GF Value $3.00
Valuation Modestly Overvalued
View Full Analysis

What is Hansoh Pharmaceutical Group Co ROCE %?

Hansoh Pharmaceutical Group Co HNSPF 90 ROCE % is 17.26% as of Dec. 2025. GuruFocus rates HNSPF with a GF Score™ of 90/100 and a GF Value™ of $3.00 (Modestly Overvalued).

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Hansoh Pharmaceutical Group Co's annualized ROCE % for the quarter that ended in Dec. 2025 was 17.26%.

Hansoh Pharmaceutical Group Co  (OTCPK:HNSPF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Hansoh Pharmaceutical Group Co ROCE % Related Terms

Hansoh Pharmaceutical Group Co ROCE % Historical Data

* Premium members only.

The historical data trend for Hansoh Pharmaceutical Group Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hansoh Pharmaceutical Group Co ROCE % Chart

Hansoh Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.05 11.18 14.14 18.30 20.63

Hansoh Pharmaceutical Group Co Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.19 22.78 13.74 24.58 17.26
HNSPF
90GF Score
Hansoh Pharmaceutical Group Co Ltd HNSPF
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hansoh Pharmaceutical Group Co ROCE % Calculation

Hansoh Pharmaceutical Group Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=930.506/( ( (4348.188 - 370.187) + (5665.088 - 623.997) )/ 2 )
=930.506/( (3978.001+5041.091)/ 2 )
=930.506/4509.546
=20.63 %

Hansoh Pharmaceutical Group Co's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=813.254/( ( (4884.322 - 501.503) + (5665.088 - 623.997) )/ 2 )
=813.254/( ( 4382.819 + 5041.091 )/ 2 )
=813.254/4711.955
=17.26 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 17.26% mean?
Hansoh Pharmaceutical Group Co (HNSPF) has a ROCE % of 17.26% as of Dec. 2025.
Is Hansoh Pharmaceutical Group Co's ROCE % too high?
Hansoh Pharmaceutical Group Co's current ROCE % is 17.26%. The Drug Manufacturers industry median ROCE % is 7.03. Hansoh Pharmaceutical Group Co's value of 17.26% is 145.5% above this industry median. Overall, Hansoh Pharmaceutical Group Co has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hansoh Pharmaceutical Group Co's ROCE % compare to ZTS and UTHR?
Hansoh Pharmaceutical Group Co's ROCE % of 17.26% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.03. Hansoh Pharmaceutical Group Co's value of 17.26% is 145.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.03, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hansoh Pharmaceutical Group Co's current ROCE % of 17.26% is 145.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hansoh Pharmaceutical Group Co's current ROCE % is 17.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansoh Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co (HNSPF) is currently considered Modestly Overvalued. The stock's GF Value™ is $3.00, compared to a current price of $3.83 — trading 27.5% above its estimated fair value. The current ROCE % is 17.26% and 145.5% above the Drug Manufacturers industry median of 7.03. Hansoh Pharmaceutical Group Co's overall GF Score™ is 90/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Hansoh Pharmaceutical Group Co (HNSPF), the current ROCE % is 17.26% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hansoh Pharmaceutical Group Co (HNSPF) Overvalued in 2026?

Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co stock appears to be overvalued. The current stock price of $3.83 is trading 27.5% above its estimated GF Value™ of $3.00. GuruFocus considers Hansoh Pharmaceutical Group Co to be Modestly Overvalued.

Key valuation signals for HNSPF:

  • ROCE %: 17.26%
  • GF Value™: $3.00 vs. price of $3.83 (27.5% above fair value)
  • GF Score™: 90/100
  • Industry Position: 145.5% above the Drug Manufacturers median

No single metric tells the full story. See the HNSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hansoh Pharmaceutical Group Co Business Description

Address No. 287 Xiangke Road, Pudong New Area, Shanghai, CHN
Hansoh Pharmaceutical Group Co Ltd is an investment holding company. The company were principally engaged in the research and development, production and sale of a series of pharmaceutical products in the People's Republic of China. It focuses on disease therapeutic areas such as oncology, anti-infectives, CNS, metabolism and immunology. The majority of Group's revenue was generated from the sale of pharmaceutical products in Chinese mainland.
90GF Score

Get the complete analysis for HNSPF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.83
Price
$3.00
GF Value